Previous 10 | Next 10 |
The following slide deck was published by Cara Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Cara Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
Cara Therapeutics, Inc. (CARA) Q1 2021 Earnings Conference Call May 10, 2021 16:30 ET Company Participants Jack Hildick-Smith - Investor Relations Derek Chalmers - Chief Executive Officer Thomas Reilly - Chief Financial Officer Conference Call Participants Chris Howerton - Jefferies David Ams...
Image source: The Motley Fool. Cara Therapeutics Inc (NASDAQ: CARA) Q1 2021 Earnings Call May 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Cara Therapeutics Inc (CARA) Q1 2021 Earnings Call Transcript
Cara Therapeutics (CARA): Q1 GAAP EPS of -$0.47 beats by $0.12.Revenue of $1.94M (-76.0% Y/Y) misses by $0.65M.Cash, cash equivalents and marketable securities at March 31, 2021 totaled $228.3 million compared to $251.5 million at December 31, 2020. Guidance: Cara expects that its existi...
– U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA™ Injection in CKD-aP – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- ...
STAMFORD, Conn., May 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announc...
STAMFORD, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announc...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks fell broadly Friday, as investors took profits following a flurry of earnings reports, including a blowout quarter from Amazon, and an...
Gainers: Willamette Valley Vineyards (WVVI) +55%.Ocular Therapeutix (OCUL) +23%.Galera Therapeutics (GRTX) +23%.JAKKS Pacific (JAKK) +21%.ShiftPixy (PIXY) +19%.1-800-FLOWERS.COM (FLWS) +18%.MEDIROM Healthcare Technologies (MRM) +16%.VEREIT (VER) +16%.Communications Systems (JCS) +15%.Dol...
Shares of Cara Therapeutics (NASDAQ: CARA) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis. ...
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...